Date: 2014-06-23
Type of information: Licensing agreement
Compound:
Company: Treeway (The Netherlands) Amarna Therapeutics (The Netherlands)
Therapeutic area: Neurodegenerative diseases - Rare diseases
Type agreement: licensing
Action mechanism: new therapeutic targets for the treatment of amyotrophic lateral sclerosis
Disease: amyotrophic lateral sclerosis
Details: * On June 23, 2014, Treeway and Amarna Therapeutics announced they have joined forces and formed a collaboration to identify new therapeutic targets for the treatment of amyotrophic lateral sclerosis (ALS). The aim of the project is to screen for new targets which play a role in both the cause and progression of ALS using the patented viral gene delivery platform SVac. The objective of this collaboration is to investigate the role of the adaptive immune system in ALS, with the final aim to develop a reverse vaccine to stop disease progression. This research will lead to new insights in both the cause and progression of ALS.
Financial terms:
Latest news:
